<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <!--The publisher of this article does not allow downloading of the full text in XML form.-->
  <?properties manuscript?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">101123358</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">29775</journal-id>
      <journal-id journal-id-type="nlm-ta">Expert Rev Anticancer Ther</journal-id>
      <journal-id journal-id-type="iso-abbrev">Expert Rev Anticancer Ther</journal-id>
      <journal-title-group>
        <journal-title>Expert review of anticancer therapy</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1473-7140</issn>
      <issn pub-type="epub">1744-8328</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25695344</article-id>
      <article-id pub-id-type="pmc">4457617</article-id>
      <article-id pub-id-type="doi">10.1586/14737140.2015.1016425</article-id>
      <article-id pub-id-type="manuscript">NIHMS695756</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Die-hard survivors: heterogeneity in apoptotic thresholds may underlie chemoresistance</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ogden</surname>
            <given-names>Angela</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rida</surname>
            <given-names>Padmashree CG</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Reid</surname>
            <given-names>Michelle D.</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kucuk</surname>
            <given-names>Omer</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aneja</surname>
            <given-names>Ritu</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref rid="FN1" ref-type="author-notes">*</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Biology, Georgia State University, Atlanta, GA 30303, USA</aff>
      <aff id="A2"><label>2</label>Department of Pathology, Emory University Hospital, Atlanta, GA 30322, USA</aff>
      <aff id="A3"><label>3</label>Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA</aff>
      <author-notes>
        <corresp id="FN1"><label>*</label>Author for correspondence: Tel.: +1 404 413 5417, Fax: +1 404 413 5301, <email>raneja@gsu.edu</email></corresp>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>2</day>
        <month>6</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>19</day>
        <month>2</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>05</day>
        <month>6</month>
        <year>2015</year>
      </pub-date>
      <volume>15</volume>
      <issue>3</issue>
      <fpage>277</fpage>
      <lpage>281</lpage>
      <!--elocation-id from pubmed: 10.1586/14737140.2015.1016425-->
      <permissions>
        <copyright-statement>© 2015 Informa UK Ltd</copyright-statement>
        <copyright-year>2015</copyright-year>
      </permissions>
      <abstract>
        <p id="P1">The unmatched efficacy of microtubule-targeting agents (MTAs) as chemotherapeutics was once assumed to originate from their impact on mitotic processes; however, this misconception is being eroded by amassing data that MTAs instead target interphase functions in patients’ tumors. What remains murky is how MTAs target malignant cells over non-malignant ones if proliferation rates do not distinguish them. In many instances, malignant cells are actually more ‘primed’ for apoptosis than non-malignant ones. Nevertheless, even if most cells within the tumor are more apoptosis-susceptible than those in healthy tissues, there likely exist small subpopulations of apoptosis-resistant clones that engender incomplete responses to MTAs and relapse. Therefore, intratumor heterogeneity in terms of proximity to the apoptotic threshold must be better understood to facilitate the design of chemotherapeutic regimens, which may benefit from including drugs like BH3 mimetics that help in lowering the apoptotic threshold of tumor cells within these chemoresistant subpopulations.</p>
      </abstract>
      <kwd-group>
        <kwd>apoptotic threshold</kwd>
        <kwd>chemoresistance</kwd>
        <kwd>intratumor heterogeneity</kwd>
        <kwd>mitochondrial priming</kwd>
        <kwd>tubulin inhibitors</kwd>
      </kwd-group>
    </article-meta>
  </front>
</article>

